Cover Image
市場調查報告書

東南亞的第二型糖尿病治療藥的市場

Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

出版商 GBI Research 商品編碼 369233
出版日期 內容資訊 英文 176 Pages
訂單完成後即時交付
價格
Back to Top
東南亞的第二型糖尿病治療藥的市場 Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth
出版日期: 2016年08月01日 內容資訊: 英文 176 Pages
簡介

第二型糖尿病的治療方法這10年來飛躍性地進步,尤其是新治療藥不斷上市變。治療選擇也很廣泛,提供各種標的對象的治療藥。儘管如此,關於血糖管理和併發症 (糖尿病性神經症、視網膜症、心血管疾病等)的預防、治療,仍存在著巨大的未滿足需求。

本報告提供東南亞各國的第二型糖尿病 (T2DM) 治療藥的市場現況與未來展望相關分析,第二型糖尿病概要、特性,及現在已上市的產品概要,現在臨床實驗中的開發中產品一覽和臨床實驗的進展,今後的市場成長、技術開發 (臨床實驗進展)的預測,主要企業的概要與競爭策略,今後的資本交易、產業重組預測等相關調查與考察。

第1章 目錄

第2章 簡介

  • 疾病概要
  • 流行病學
  • 症狀
  • 病因、病理生理學
  • 診斷方法
  • 分類
  • 預後
  • 治療選擇
    • 治療流程
    • 非胰島素療法
    • 胰島素療法
  • 治療方法的分類
    • 非胰島素療法
    • 胰島素療法
  • 共生病症和併發症

第3章 已上市產品

  • 概要
  • 雙胍類系
    • Metformin
  • 磺醯尿素類
  • 胰島素增敏劑
    • PIOGLITAZONE
    • Duvie (robeguritazon) - Chong Kun Dang
  • GLP-1受體激動劑
    • Byetta (exenatide) - Eli Lilly
    • Bydureon (exenatide) - AstraZeneca
    • Victoza (liraglutide) - Novo Nordisk
    • Lyxumia (lixisenatide) - Sanofi
    • Tanzeum (albiglutide) - GlaxoSmithKline
  • DPP-4抑制劑
    • Januvia (sitagliptin) - Merck
    • Galvus (vildagliptin) - Novartis
    • Onglyza (saxagliptin) - Bristol-Myers Squibb/AstraZeneca
    • Trajenta (linagliptin) - Bristol-Myers Squibb/AstraZeneca
    • Zemiglo (gemigliptin) - LG Life Sciences
    • Suganon (evogliptin) - Dong-A ST
    • Gadret (anagliptin) - JW Pharmaceutical
    • Nesina (alogliptin) - Takeda
    • Tenelia (teneligliptin) - Mitsubishi Tanabe Pharma
  • SGLT-2抑制劑
    • Forxiga (dapagliflozin) - AstraZeneca
    • Invokana (canagliflozin) - Janssen
    • Jardiance (empagliflozin) - Boehringer Ingelheim
    • Suglat (ipragliflozin) - Astellas
  • 胰島素療法
    • Lantus (Insulin glargine) - Sanofi
    • Levemir (Insulin Detemir) - Novo Nordisk
    • Tresiba (Insulin Degludec) - Novo Nordisk
    • Toujeo (insulin glargine) - Sanofi
  • 已上市產品的相對的功效、安全性

第4章 開發中產品

  • 概要
  • 開發中產品一覽:臨床實驗的各階段,各分子類型,各投藥途徑,計劃的各類型
  • 開發中產品一覽:各分子標的
  • 有前途的開發平台(管線)候補藥
    • NN-9535(subcutaneous semaglutide) and OG-217SC (oral semaglutide) - Novo Nordisk
    • Trulicity (dulaglutide)
    • Ertugliflozin - Pfizer
    • Bexagliflozin - Theracos
    • Omarigliptin - Merck
  • 開發中產品的產品相對功效、安全性
  • 產品競爭的組成架構

第5章 臨床實驗分析

  • 失敗率
    • 整體失敗率
    • 各相位、各分子類型的失敗率
    • 各相位、各分子標的失敗率
  • 臨床實驗的規模
  • 臨床實驗的期間
    • 臨床實驗期間:各開發階段、各分子類型
    • 臨床實驗期間:各開發階段、各分子標的
  • 臨床實驗的相關指標:摘要

第6章 多方案預測

  • 各地區市場
  • 東南亞市場
  • 韓國
    • 治療藥的利用模式
    • 年度治療費用
    • 市場規模
  • 新加坡
  • 台灣
  • 馬來西亞
  • 菲律賓
  • 泰國
  • 越南
  • 印尼

第7章 市場動態 (促進、阻礙因素)

  • 推動市場要素
    • 人口高齡化,肥胖人口的增加,經濟發展
    • 對第二型糖尿病的知識擴大
    • 認證藥物類別的連續性的上市、普及
    • 臨床實驗的最後階段有潛力的開發中產品,改變治療範例的可能性
    • 聯合治療的利用擴大
  • 市場阻礙因素
    • 非藥理性的一次選擇治療
    • 非專利醫藥品的使用擴大
    • 治療方針的遵守度低
    • 專利到期伴隨的產品的一般化、利益消失

第8章 資本交易與業界重組

  • 授權合約交易
    • 各地區的交易趨勢/金額
    • 年度交易量及總合交易金額的變化
    • 各臨床實驗階段、各分子類型、各分子標的交易金額
    • 主要的授權合約交易
  • 共同開發交易

第9章 附錄

  • 全開發中產品:各相位
  • 各國市場的未來預測 (到2022年)
  • 參考文獻
  • 簡稱一覽
  • 分析方法
  • 聯絡處資訊
  • 免責聲明

圖表一覽

目錄
Product Code: GBIHC421MR

Executive Summary

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 90-95% of all diabetics have T2DM.

T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control, as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.

Scope

The current South-East Asia T2DM market contains novel products, including Jardiance, a SGLT-2 inhibitor; Victoza, a GLP-1 receptor agonist; and Januvia, a DPP-4 inhibitor.

  • What are the competitive advantages of the existing novel drugs?

With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, featuring improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.

  • Which classes of novel drugs are most prominent within the pipeline?
  • Is there strong potential for the pipeline to address unmet needs within the T2DM market?

Analysis of clinical trials since 2006 identified that the failure rates of T2DM molecules were highest in Phase III, at 49%, with the overall attrition rate for T2DM standing at 75%.

  • How do failure rates vary by product stage of development, molecule type, and mechanism of action?
  • How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?

Over the 2015-2022 forecast period, the South-East Asia T2DM therapeutics market is expected to increase in value at a CAGR of 7.1%, from $1.7 billion to over $2.7 billion.

  • Which markets make the most significant contribution to the current market size?
  • What are the epidemiology trends in these markets?
  • Will new market entrants lead to substantial changes in annual therapy costs?
  • How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?

Rising T2DM prevalence and the uptake of newer therapies will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations.

  • Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?

Reasons to buy

This report will enable you to -

  • Understand the clinical context of T2DM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
  • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
  • Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
  • Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
  • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections.
  • Compare treatment usage patterns, annual therapy costs, and market growth projections for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.
  • Discover trends in licensing and co-development deals concerning T2DM products and identify the major strategic consolidations that have shaped the commercial landscape.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Epidemiology
  • 2.3. Symptoms
  • 2.4. Etiology and Pathophysiology
  • 2.5. Diagnosis
  • 2.6. Classification
  • 2.7. Prognosis
  • 2.8. Treatment Options
    • 2.8.1. Treatment Algorithm
    • 2.8.2. Non-insulin T2DM Therapies
    • 2.8.3. Insulin T2DM Therapies
  • 2.9. Treatment Segments
    • 2.9.1. Non-insulin therapies
    • 2.9.2. Insulin Therapies
  • 2.10. Co-morbidities and Complications

3. Marketed Products

  • 3.1. Overview
  • 3.2. Biguanides
    • 3.2.1. Metformin
  • 3.3. Sulfonylureas
  • 3.4. Thiazolidinediones
    • 3.4.1. Pioglitazone
    • 3.4.2. Duvie (lobeglitazone) - Chong Kun Dang
  • 3.5. GLP-1 Receptor Agonists
    • 3.5.1. Byetta (exenatide) - Eli Lilly
    • 3.5.2. Bydureon (exenatide) - AstraZeneca
    • 3.5.3. Victoza (liraglutide) - Novo Nordisk
    • 3.5.4. Lyxumia (lixisenatide) - Sanofi
    • 3.5.5. Tanzeum (albiglutide) - GlaxoSmithKline
  • 3.6. DPP-4 Inhibitors
    • 3.6.1. Januvia (sitagliptin) - Merck
    • 3.6.2. Galvus (vildagliptin) - Novartis
    • 3.6.3. Onglyza (saxagliptin) - Bristol-Myers Squibb/AstraZeneca
    • 3.6.4. Trajenta (linagliptin) - Bristol-Myers Squibb/AstraZeneca
    • 3.6.5. Zemiglo (gemigliptin) - LG Life Sciences
    • 3.6.6. Suganon (evogliptin) - Dong-A ST
    • 3.6.7. Gadret (anagliptin) - JW Pharmaceutical
    • 3.6.8. Nesina (alogliptin) - Takeda
    • 3.6.9. Tenelia (teneligliptin) - Mitsubishi Tanabe Pharma
  • 3.7. SGLT-2 Inhibitors
    • 3.7.1. Forxiga (dapagliflozin) - AstraZeneca
    • 3.7.2. Invokana (canagliflozin) - Janssen
    • 3.7.3. Jardiance (empagliflozin) - Boehringer Ingelheim
    • 3.7.4. Suglat (ipragliflozin) - Astellas
  • 3.8. Insulin Therapies
    • 3.8.1. Lantus (insulin glargine) - Sanofi
    • 3.8.2. Levemir (insulin detemir) - Novo Nordisk
    • 3.8.3. Tresiba (insulin degludec) - Novo Nordisk
    • 3.8.4. Toujeo (insulin glargine) - Sanofi
  • 3.9. Comparative Efficacy and Safety of Marketed Products

4. Pipeline

  • 4.1. Overview
  • 4.2. Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
  • 4.3. Pipeline by Molecular Target
  • 4.4. Promising Pipeline Candidates
    • 4.4.1. NN-9535(subcutaneous semaglutide) and OG-217SC (oral semaglutide) - Novo Nordisk
    • 4.4.2. Trulicity (dulaglutide)
    • 4.4.3. Ertugliflozin - Pfizer
    • 4.4.4. Bexagliflozin - Theracos
    • 4.4.5. Omarigliptin - Merck
  • 4.5. Comparative Efficacy and Safety of Pipeline Products
  • 4.6. Product Competitive Framework

5. Clinical Trial Analysis

  • 5.1. Failure Rate
    • 5.1.1. Overall Failure Rate
    • 5.1.2. Failure Rate by Phase and Molecule Type
    • 5.1.3. Failure Rate by Phase and Molecular Target
  • 5.2. Clinical Trial Size
  • 5.3. Clinical Trial Duration
    • 5.3.1. Trial Duration by Stage of Development and Molecule Type
    • 5.3.2. Trial Duration by Stage of Development and Molecular Target
  • 5.4. Summary of Clinical Trial Metrics

6. Multi-Scenario Forecast

  • 6.1. Geographical Markets
  • 6.2. South-East Asia Markets
  • 6.3. South Korea
    • 6.3.1. Treatment Usage Patterns
    • 6.3.2. Annual Cost of Therapy
    • 6.3.3. Market Size
  • 6.4. Singapore
    • 6.4.1. Treatment Usage Patterns
    • 6.4.2. Annual Cost of Therapy
    • 6.4.3. Market Size
  • 6.5. Taiwan
    • 6.5.1. Treatment Usage Patterns
    • 6.5.2. Annual Cost of Therapy
    • 6.5.3. Market Size
  • 6.6. Malaysia
    • 6.6.1. Treatment Usage Patterns
    • 6.6.2. Annual Cost of Therapy
    • 6.6.3. Market Size
  • 6.7. Philippines
    • 6.7.1. Treatment Usage Patterns
    • 6.7.2. Annual Cost of Therapy
    • 6.7.3. Market Size
  • 6.8. Thailand
    • 6.8.1. Treatment Usage Patterns
    • 6.8.2. Annual Cost of Therapy
    • 6.8.3. Market Size
  • 6.9. Vietnam
    • 6.9.1. Treatment Usage Patterns
    • 6.9.2. Annual Cost of Therapy
    • 6.9.3. Market Size
  • 6.10. Indonesia
    • 6.10.1. Treatment Usage Patterns
    • 6.10.2. Annual Cost of Therapy
    • 6.10.3. Market Size

7. Market Dynamics, (Drivers and Barriers)

  • 7.1. Drivers
    • 7.1.1. Aging Population, Increasing Obesity and Growing Economy
    • 7.1.2. Increasing Awareness of T2DM
    • 7.1.3. Continued Uptake of Recently Approved Drug Classes
    • 7.1.4. Promising Late-Stage Pipeline Products can Change the Treatment Paradigm
    • 7.1.5. Enhanced Usage of Combination Therapies
  • 7.2. Barriers
    • 7.2.1. Non-pharmacological First-line Treatment
    • 7.2.2. Widespread Usage of Generic Drugs
    • 7.2.3. Poor Adherence to Treatment Regimens
    • 7.2.4. Generic Erosion Resulting from Patent Expirations

8. Deals and Strategic Consolidations

  • 8.1. Licensing Deals
    • 8.1.1. Deals by Region and Value
    • 8.1.2. Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
    • 8.1.3. Deal Value by Stage of Development, Molecule Type, and Molecular Target
    • 8.1.4. Key Licensing Deals
  • 8.2. Co-development Deals
    • 8.2.1. Deals by Region and Value
    • 8.2.2. Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
    • 8.2.3. Deal Value by Stage of Development, Molecule Type, and Molecular Target
    • 8.2.4. Key Co-Development Deals

9. Appendix

  • 9.1. All Pipeline Drugs by Phase of Development
    • 9.1.1. Discovery
    • 9.1.2. Preclinical
    • 9.1.3. IND/CTA-filed
    • 9.1.4. Phase I
    • 9.1.5. Phase II
    • 9.1.6. Phase III
    • 9.1.7. Pre-registration
  • 9.2. Market Forecasts to 2022
    • 9.2.1. South-East Asia
    • 9.2.2. South Korea
    • 9.2.3. Singapore
    • 9.2.4. Taiwan
    • 9.2.5. Malaysia
    • 9.2.6. Philippines
    • 9.2.7. Thailand
    • 9.2.8. Vietnam
    • 9.2.9. Indonesia
  • 9.3. References
  • 9.4. Abbreviations
  • 9.5. Research Methodology
    • 9.5.1. Secondary Research
    • 9.5.2. Marketed Product Profiles
    • 9.5.3. Late-Stage Pipeline Candidates
    • 9.5.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 9.5.5. Pipeline Analysis
    • 9.5.6. Forecasting Model
    • 9.5.7. Deals Data Analysis
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Dose Levels for Groups Initially Receiving Metformin in Combination with Glyburide, Metformin Monotherapy and Glyburide Monotherapy
  • Table 2: T2DM Therapeutics, Global, All Pipeline Products, Discovery Stage, March 2016
  • Table 3: T2DM Therapeutics, Global, All Pipeline Products, Preclinical Stage, March 2016
  • Table 4: T2DM Therapeutics, Global, All Pipeline Products, IND/CTA-filed Stage, March 2016
  • Table 5: T2DM Therapeutics, Global, All Pipeline Products, Phase I, March 2016
  • Table 6: T2DM Therapeutics, Global, All Pipeline Products, Phase II, March 2016
  • Table 7: T2DM Therapeutics, Global, All Pipeline Products, Phase III, March 2016
  • Table 8: T2DM Therapeutics, Global, All Pipeline Products, Pre-registration Stage, March 2016
  • Table 9: T2DM Therapeutics Market, South-East Asia, Market Forecast, 2015-2022
  • Table 10: T2DM Therapeutics Market, South Korea, Market Forecast, 2015-2022
  • Table 11: T2DM Therapeutics Market, Singapore, Market Forecast, 2015-2022
  • Table 12: T2DM Therapeutics Market, Taiwan, Market Forecast, 2015-2022
  • Table 13: T2DM Therapeutics Market, Malaysia, Market Forecast, 2015-2022
  • Table 14: T2DM Therapeutics Market, Philippines, Market Forecast, 2015-2022
  • Table 15: T2DM Therapeutics Market, Thailand, Market Forecast, 2015-2022
  • Table 16: T2DM Therapeutics Market, Vietnam, Market Forecast, 2015-2022
  • Table 17: T2DM Therapeutics Market, Indonesia, Market Forecast, 2015-2022

List of Figures

  • Figure 1: T2DM Therapeutics Market, South-East Asia, Heat Map for Marketed Products, 2016
  • Figure 2: T2DM Therapeutics Market, South-East Asia, Heat Map for Marketed Products, 2016 (continued)
  • Figure 3: T2DM Therapeutics Market, Global, Pipeline, 2016
  • Figure 4: T2DM Therapeutics Market, Global, Pipeline by Molecular Target, 2016
  • Figure 5: T2DM Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016
  • Figure 6: T2DM Therapeutics Market, South-East Asia, NN-9535 Forecast ($m), 2018-2022
  • Figure 7: T2DM Therapeutics Market, South-East Asia, OG-217SC Forecast ($m), 2020-2022
  • Figure 8: T2DM Therapeutics Market, South-East Asia, Trulicity Products Forecast ($m), 2016-2022
  • Figure 9: T2DM Therapeutics Market, South-East Asia, Ertugliflozin Products Forecast ($m), 2018-2022
  • Figure 10: T2DM Therapeutics Market, South-East Asia, Bexagliflozin Products Forecast ($m), 2020-2022
  • Figure 11: T2DM Therapeutics Market, South-East Asia, Omarigliptin Products Forecast ($m), 2017-2022
  • Figure 12: T2DM Market, South-East Asia, Heat Map for Pipeline Products, March 2016
  • Figure 13: T2DM Therapeutics Market, South-East Asia, Competitor Matrix for Marketed and Pipeline Products, March 2016
  • Figure 14: T2DM Therapeutics, Global, Clinical Trial Attrition Rates (%), 2006-March 2016
  • Figure 15: T2DM Therapeutics, Global, Clinical Trial Attrition Rates by Molecule Type (%), 2006-March 2016
  • Figure 16: T2DM Therapeutics, Global, Clinical Trial Attrition Rates by Molecular Target (%), 2006-March 2016
  • Figure 17: T2DM Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-March 2016
  • Figure 18: T2DM Therapeutics, Global, Clinical Trial Size per Product Molecular Target (participants), 2006-March 2016
  • Figure 19: T2DM Therapeutics, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2006-March 2016
  • Figure 20: T2DM Therapeutics, Global, Clinical Trial Size per Individual Trial by Molecular Target (participants), 2006-March 2016
  • Figure 21: T2DM Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006-March 2016
  • Figure 22: T2DM Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2006-March 2016
  • Figure 23: T2DM Therapeutics, Global, Comparison of Average Trial Metrics by Phase and Molecule Type, 2006-March 2016
  • Figure 24: T2DM Therapeutics, Global, Comparison of Average Trial Metrics by Phase and Molecular Target, 2006-March 2016
  • Figure 25: T2DM Therapeutics Market, South-East Asia, Treatment Usage Patterns (million), 2015-2022
  • Figure 26: T2DM Therapeutics Market, South-East Asia, Market Size ($bn), 2015-2022
  • Figure 27: T2DM Therapeutics Market, South Korea, Treatment Usage Patterns (million), 2015-2022
  • Figure 28: T2DM Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015-2022
  • Figure 29: T2DM Therapeutics Market, South Korea, Market Size ($m), 2015-2022
  • Figure 30: T2DM Therapeutics Market, Singapore, Treatment Usage Patterns (million), 2015-2022
  • Figure 31: T2DM Therapeutics Market, Singapore, Annual Cost of Therapy ($), 2015-2022
  • Figure 32: T2DM Therapeutics Market, Singapore, Market Size ($m), 2015-2022
  • Figure 33: T2DM Therapeutics Market, Taiwan, Treatment Usage Patterns (million), 2015-2022
  • Figure 34: T2DM Therapeutics Market, Taiwan, Annual Cost of Therapy ($), 2015-2022
  • Figure 35: T2DM Therapeutics Market, Taiwan, Market Size ($m), 2015-2022
  • Figure 36: T2DM Therapeutics Market, Malaysia, Treatment Usage Patterns (million), 2015-2022
  • Figure 37: T2DM Therapeutics Market, Malaysia, Annual Cost of Therapy ($), 2015-2022
  • Figure 38: T2DM Therapeutics Market, Malaysia, Market Size ($m), 2015-2022
  • Figure 39: T2DM Therapeutics Market, Philippines, Treatment Usage Patterns (million), 2015-2022
  • Figure 40: T2DM Therapeutics Market, Philippines, Annual Cost of Therapy ($), 2015-2022
  • Figure 41: T2DM Therapeutics Market, Philippines, Market Size ($m), 2015-2022
  • Figure 42: T2DM Therapeutics Market, Thailand, Treatment Usage Patterns (million), 2015-2022
  • Figure 43: T2DM Therapeutics Market, Thailand, Annual Cost of Therapy ($), 2015-2022
  • Figure 44: T2DM Therapeutics Market, Thailand, Market Size ($m), 2015-2022
  • Figure 45: T2DM Therapeutics Market, Vietnam, Treatment Usage Patterns (million), 2015-2022
  • Figure 46: T2DM Therapeutics Market, Vietnam, Annual Cost of Therapy ($), 2015-2022
  • Figure 47: T2DM Therapeutics Market, Vietnam, Market Size ($m), 2015-2022
  • Figure 48: T2DM Therapeutics Market, Indonesia, Treatment Usage Patterns (million), 2015-2022
  • Figure 49: T2DM Therapeutics Market, Indonesia, Annual Cost of Therapy ($), 2015-2022
  • Figure 50: T2DM Therapeutics Market, Indonesia, Market Size ($m), 2015-2022
  • Figure 51: T2DM Therapeutics Market, Global, Licensing Deals by Deal Value, 2006-March 2016
  • Figure 52: T2DM Therapeutics Market, Global, Licensing Deals by Region, 2006-March 2016
  • Figure 53: T2DM Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-March 2016
  • Figure 54: T2DM Therapeutics Market, Global, Licensing Deals by Deal Value ($m), Upfront Payment Value ($m) and Stage of Development, 2006-March 2016
  • Figure 55: T2DM Therapeutics Market, Global, Licensing Deals by Stage of Development, Molecule Type and Aggregate Deal Value ($bn), 2006-March 2016
  • Figure 56: T2DM Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006-March 2016
  • Figure 57: T2DM Therapeutics Market, Global, Co-development Deals by Value ($m), 2006-March 2016
  • Figure 58: T2DM Therapeutics Market, Global, Co-Development Deals by Region, 2006-March 2016
  • Figure 59: T2DM Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-Development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006-March 2016
  • Figure 60: T2DM Therapeutics Market, Global, Co-development Deals by Deal Value ($m), Upfront Payment Value ($m) and Stage of Development, 2006-March 2016
  • Figure 61: T2DM Therapeutics Market, Global, Co-development Deals by Stage of Development, Molecule Type and Aggregate Deal Value ($bn), 2006-March 2016
  • Figure 62: T2DM Therapeutics Market, Global, Co-Development Deals by Molecular Target and Aggregate Deal Value ($m), 2006-March 2016
Back to Top